• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《韩国癌症统计:2016 年发病率、死亡率、生存率和流行率》

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016.

机构信息

The Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.

National Cancer Control Institute, National Cancer Center, Goyang, Korea.

出版信息

Cancer Res Treat. 2019 Apr;51(2):417-430. doi: 10.4143/crt.2019.138. Epub 2019 Mar 18.

DOI:10.4143/crt.2019.138
PMID:30913865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6473271/
Abstract

PURPOSE

This study presents the 2016 nationwide cancer statistics in Korea, including cancer incidence, survival, prevalence, and mortality.

MATERIALS AND METHODS

Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database and followed until December 31, 2017. Mortality data from 1983 to 2016 were obtained from Statistics Korea. The prevalence was defined as the number of cancer patients alive on January 1, 2017 among all cancer patients diagnosed since 1999. Crude and age-standardized rates (ASRs) for incidence, mortality, and prevalence and 5-year relative survivals were also calculated.

RESULTS

Overall, 229,180 and 78,194 Koreans were newly diagnosed and died from cancer in 2016, respectively. The ASRs for cancer incidence and mortality in 2016 were 269.0 and 79.8 per 100,000 individuals, respectively. The all-cancer incidence rate increased significantly by 3.6% annually from 1999 to 2011 and started to decrease after 2011 (2011-2016; annual percent change, -3.1%). However, overall cancer mortality has decreased 2.7% annually since 2002. The 5-year relative survival rate for patients diagnosed with cancer between 2012 and 2016 was 70.6%, an improvement from the 41.2% for patients diagnosed between 1993 and 1995.

CONCLUSION

The cancer prevalence in Korea has increased very fast as survival has improved remarkably. The high prevalence of cancer emphasizes the need for comprehensive cancer control efforts in Korea.

摘要

目的

本研究呈现了韩国 2016 年全国癌症统计数据,包括癌症发病率、生存率、患病率和死亡率。

材料和方法

1999 年至 2016 年的癌症发病率数据来自韩国国家癌症发病率数据库,并随访至 2017 年 12 月 31 日。1983 年至 2016 年的死亡率数据来自韩国统计局。患病率定义为 2017 年 1 月 1 日所有 1999 年以来诊断出的癌症患者中的癌症患者人数。还计算了发病率、死亡率和患病率的粗率和年龄标准化率(ASR)以及 5 年相对生存率。

结果

2016 年,韩国共有 229180 人新诊断出癌症,78194 人死于癌症。2016 年癌症发病率和死亡率的 ASR 分别为每 100000 人 269.0 和 79.8。1999 年至 2011 年,所有癌症的发病率每年以 3.6%的速度显著增加,2011 年后开始下降(2011-2016 年;年变化百分比,-3.1%)。然而,自 2002 年以来,总体癌症死亡率每年下降 2.7%。2012 年至 2016 年期间诊断出癌症的患者的 5 年相对生存率为 70.6%,高于 1993 年至 1995 年期间诊断出的患者的 41.2%。

结论

随着生存率的显著提高,韩国的癌症患病率增长非常迅速。癌症高患病率强调了韩国需要进行全面的癌症控制努力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/ada00aab0429/crt-2019-138f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/8ea24816cf84/crt-2019-138f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/9923d494cc4b/crt-2019-138f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/cdb9b7f078b0/crt-2019-138f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/daa00bf9626f/crt-2019-138f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/cee4dd938935/crt-2019-138f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/ada00aab0429/crt-2019-138f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/8ea24816cf84/crt-2019-138f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/9923d494cc4b/crt-2019-138f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/cdb9b7f078b0/crt-2019-138f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/daa00bf9626f/crt-2019-138f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/cee4dd938935/crt-2019-138f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6473271/ada00aab0429/crt-2019-138f6.jpg

相似文献

1
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016.《韩国癌症统计:2016 年发病率、死亡率、生存率和流行率》
Cancer Res Treat. 2019 Apr;51(2):417-430. doi: 10.4143/crt.2019.138. Epub 2019 Mar 18.
2
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014.韩国癌症统计数据:2014年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2017 Apr;49(2):292-305. doi: 10.4143/crt.2017.118. Epub 2017 Mar 9.
3
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015.韩国癌症统计数据:2015 年发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2018 Apr;50(2):303-316. doi: 10.4143/crt.2018.143. Epub 2018 Mar 21.
4
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013.韩国癌症统计数据:2013年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2016 Apr;48(2):436-50. doi: 10.4143/crt.2016.089. Epub 2016 Mar 3.
5
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017.韩国癌症统计数据:2017 年发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2020 Apr;52(2):335-350. doi: 10.4143/crt.2020.206. Epub 2020 Mar 16.
6
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018.《韩国癌症统计数据:2018 年发病率、死亡率、生存率和流行率》
Cancer Res Treat. 2021 Apr;53(2):301-315. doi: 10.4143/crt.2021.291. Epub 2021 Mar 17.
7
Prediction of Cancer Incidence and Mortality in Korea, 2017.《2017年韩国癌症发病率和死亡率预测》
Cancer Res Treat. 2017 Apr;49(2):306-312. doi: 10.4143/crt.2017.130. Epub 2017 Mar 17.
8
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019.韩国癌症统计数据:2019 年的发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2022 Apr;54(2):330-344. doi: 10.4143/crt.2022.128. Epub 2022 Mar 16.
9
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020.韩国癌症统计数据:2020 年发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2023 Apr;55(2):385-399. doi: 10.4143/crt.2023.447.
10
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021.《韩国癌症统计数据:2021 年发病率、死亡率、生存率和患病率》。
Cancer Res Treat. 2024 Apr;56(2):357-371. doi: 10.4143/crt.2024.253. Epub 2024 Mar 13.

引用本文的文献

1
Long-Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea.胃溃疡患者根除幽门螺杆菌后胃癌的长期风险:韩国一项全国性队列研究
Helicobacter. 2025 Jul-Aug;30(4):e70057. doi: 10.1111/hel.70057.
2
Global landscape of early-onset thyroid cancer: current burden, temporal trend and future projections on the basis of GLOBOCAN 2022.早发性甲状腺癌的全球概况:基于GLOBOCAN 2022的当前负担、时间趋势及未来预测
J Glob Health. 2025 Apr 11;15:04113. doi: 10.7189/jogh.15.04113.
3
Temporal trends of liver cancer burden, comparative analysis of risk factors and trend forecasts to 2024 in China, USA, the Republic of Korea, and Mongolia: an analysis based on multiple data sources from Global Burden of Disease 2019, the Global Cancer Observatory, and Cancer Incidence in Five Continents.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015.韩国癌症统计数据:2015 年发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2018 Apr;50(2):303-316. doi: 10.4143/crt.2018.143. Epub 2018 Mar 21.
3
Prediction of Cancer Incidence and Mortality in Korea, 2016.
中国、美国、韩国和蒙古肝癌负担的时间趋势、风险因素比较分析及到2024年的趋势预测:基于全球疾病负担研究2019、全球癌症观测站和五大洲癌症发病率多个数据源的分析
J Glob Health. 2025 Jan 31;15:04040. doi: 10.7189/jogh.15.04040.
4
Digestive cancers: mechanisms, therapeutics and management.消化系统癌症:机制、治疗方法与管理
Signal Transduct Target Ther. 2025 Jan 15;10(1):24. doi: 10.1038/s41392-024-02097-4.
5
Symptom burden, palliative care knowledge, and palliative care needs in advanced gynecological cancer patients in Korea.韩国晚期妇科癌症患者的症状负担、姑息治疗知识和姑息治疗需求。
Support Care Cancer. 2024 Aug 10;32(9):582. doi: 10.1007/s00520-024-08772-0.
6
Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022.癌症发病率和死亡率的社会经济不平等:基于 GLOBOCAN 2022 的分析。
Chin Med J (Engl). 2024 Jun 20;137(12):1407-1413. doi: 10.1097/CM9.0000000000003140. Epub 2024 Apr 15.
7
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.可切除早期非小细胞肺癌患者全外显子测序与综合基因组分析的肿瘤突变负荷及突变图谱比较分析
Ther Adv Med Oncol. 2024 Mar 21;16:17588359241240657. doi: 10.1177/17588359241240657. eCollection 2024.
8
Association between Dyslipidemia and Glycated Hemoglobin in a Population-Based Study.一项基于人群的研究中血脂异常与糖化血红蛋白之间的关联。
Metabolites. 2024 Jan 26;14(2):92. doi: 10.3390/metabo14020092.
9
A Randomized Comparison of Multimodal Analgesia and Fentanyl-Based Patient-Controlled Analgesia in Women Undergoing Robot-Assisted Bilateral Axillary Breast Approach Thyroidectomy.多模式镇痛与芬太尼自控镇痛在接受机器人辅助双侧腋窝入路甲状腺切除术的女性患者中的随机对照比较。
J Clin Med. 2024 Jan 25;13(3):702. doi: 10.3390/jcm13030702.
10
Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea.人口老龄化背景下原发性中枢神经系统肿瘤流行病学模式的变化:韩国全国癌症登记数据的更新。
JCO Glob Oncol. 2024 Feb;10:e2300352. doi: 10.1200/GO.23.00352.
2016年韩国癌症发病率和死亡率预测
Cancer Res Treat. 2016 Apr;48(2):451-7. doi: 10.4143/crt.2016.092. Epub 2016 Mar 25.
4
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database.韩国 1999~2001 年全国癌症发病率;首次使用全国癌症发病率数据库的结果。
Cancer Res Treat. 2005 Dec;37(6):325-31. doi: 10.4143/crt.2005.37.6.325. Epub 2005 Dec 31.
5
[Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index].[基于人群的癌症登记处登记完整性评估指标以及利用该指标对1966年至1992年大阪癌症登记处登记率的估计]
Nihon Koshu Eisei Zasshi. 1998 Oct;45(10):1011-7.